Clinical Trial Update: A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE) [Phase 1, Phase 2]

View source ↗

Summary

Solid Biosciences is conducting the INSPIRE DUCHENNE study of SGT-003 gene therapy for Duchenne muscular dystrophy. The Phase 1/2 trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• SGT-003

Snippet

Sponsor: Solid Biosciences Inc. | Conditions: Duchenne Muscular Dystrophy | Phase 1, Phase 2 | Status: RECRUITING